Plastic and Biodegradable Stents for Complex and Refractory Benign Esophageal Strictures

Young Hee Ham; Gwang Ha Kim

doi:10.5946/ce.2014.47.4.295

Articles

Page Path: HOME > Clin Endosc > Volume 47(4); 2014 > Article

Review Plastic and Biodegradable Stents for Complex and Refractory Benign Esophageal Strictures: Young Hee Ham, Gwang Ha Kim; Clinical Endoscopy 2014;47(4):295-300.
DOI: https://doi.org/10.5946/ce.2014.47.4.295
Published online: July 28, 2014

Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

Correspondence: Gwang Ha Kim. Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: +82-51-240-7869, Fax: +82-51-244-8180, doc0224@pusan.ac.kr

• Received: March 7, 2014 • Revised: April 15, 2014 • Accepted: April 15, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

10,698 Views
149 Download
41 Web of Science
38 Crossref
39 Scopus

prev next

Full Article

Download PDF

Abstract
INTRODUCTION
SELF-EXPANDING PLASTIC STENT
BIODEGRADABLE STENT
PLASTIC AND BIODEGRADABLE STENTS: BETTER THAN METAL STENT
CONCLUSIONS
Acknowledgments
Acknowledgments
NOTES
REFERENCES

Abstract

Endoscopic stent placement is a well-accepted and effective alternative treatment modality for complex and refractory esophageal strictures. Among the currently available types of stents, the partially covered self-expanding metal stent (SEMS) has a firm anchoring effect, preventing stent migration and ensuring effective covering of a narrowed segment. However, hyperplastic tissue reaction driven by the uncovered mesh may prevent easy and safe stent removal. As an alternative, a fully covered SEMS decreases the recurrence of dysphagia caused by hyperplastic tissue ingrowth; however, it has a high migration rate. Likewise, although a self-expanding plastic stent (SEPS) reduces reactive hyperplasia, the long-term outcome is disappointing because of the high rate of stent migration. A biodegradable stent has the main benefit of not requiring stent removal in comparison with SEMS and SEPS. However, it still has a somewhat high rate of hyperplastic reaction, and the long-term outcome does not satisfy expectations. Up to now, the question of which type of stent should be recommended for the effective treatment of complex and refractory benign strictures has no clear answer. Therefore, the selection of stent type for endoscopic treatment should be individualized, taking into consideration the endoscopist's experience as well as patient and stricture characteristics.
Keywords: Stricture; Esophagus; Stents; Endoscopic treatment

INTRODUCTION

Dysphagia caused by benign esophageal strictures is a frequently encountered problem. It can negatively influence the patient's quality of life and may cause important complications such as malnutrition, weight loss, and aspiration.1 Benign esophageal strictures are caused by various disorders and procedures such as gastroesophageal reflux disease, surgery (anastomotic stricture), radiotherapy, ablative therapy, caustic ingestion, and pill-induced injury.2,3 Esophageal strictures can be divided into two types: simple and complex. Simple strictures are defined as short, focal, straight, and easy to pass through with a standard diagnostic endoscope, and are mostly caused by Schatzki rings, esophageal webs, or peptic injury. Complex strictures are longer (>2 cm), tortuous, angulated, or have a severely narrowed diameter (<12 mm) and often do not allow passage of an endoscope. Complex strictures can be mainly caused by surgery, radiotherapy, or corrosive injury.1,2 Of the two types of strictures, the complex type is difficult to treat and associated with a higher recurrence rate than the simple type. Refractory strictures have the following characteristics: an anatomic fibrotic esophageal restriction, absence of inflammation or motility disorder, and inability to achieve a diameter of ≥14 mm in five sessions of dilatations at 2-week intervals or inability to maintain a diameter of ≥14 mm for 4 weeks once this diameter has been achieved.4

Until now, serial endoscopic dilatation with bougies or balloons has been the standard treatment for esophageal strictures. Although the immediate success rate for relieving dysphagia is 80% to 90%, the recurrence rate reaches 30% to 40% during long-term follow-up, especially in complex strictures, requiring repeated dilatations or even surgery.5,6 What is worse, up to 10% of patients will not experience any meaningful improvement and be unresponsive to repeated endoscopic dilatations. In these cases, repeated sessions of dilatation without long-term clinical success are closely linked to increased physical and emotional burden to patients; thus, an alternative treatment strategy should be introduced.7,8,9 As an alternative, surgical solutions such as gastric pull-up and enteral replacement are most effective; however, many patients are not good surgical candidates because of their comorbid conditions or unwillingness to undergo surgery because of a substantial risk of morbidity and mortality.7,10,11 Endoscopic temporary placement of a self-expanding esophageal stent has been proposed as a well-accepted and effective treatment for refractory esophageal strictures owing to its longer-lasting dilatation effects, ability to maintain luminal patency, and simultaneous stretching of the strictures in comparison with dilatation procedures; moreover, its favorable outcomes, as well as lower morbidity and mortality than surgery have been reported.12,13,14 Currently, three types of esophageal stents are available: self-expanding metal stent (SEMS), self-expanding plastic stent (SEPS), and biodegradable (BD) stent (Fig. 1).2,15 This review focuses on the current experience with esophageal stents, mainly SEPS and BD stents, for complex and refractory benign esophageal strictures.

SELF-EXPANDING PLASTIC STENT

Recently, SEPS has been introduced to minimize the hyperplastic tissue reaction. SEPS can be easily removed and seems not to be inferior to metallic stent.16 Initially, SEPS was found to provide significant improvement of dysphagia and quality of life, and to decrease the number of dilatation sessions in patients with benign strictures.2,17 On the basis of these results, the use of SEPS in patients with benign esophageal strictures has been proposed as an alternative to SEMS.18 The currently available SEPS is the Polyflex stent (Boston Scientific, Natick, MA, USA), which is composed of a plastic wire and has a fully covered design with silicone and a proximal flare. This stent material has been suggested to reduce reactive tissue hyperplasia. As a result, the stent is easily removable and approved by Food and Drug Administration for the treatment of benign esophageal strictures. The use of Polyflex stents in malignant strictures has shown good relief of dysphagia, a major complication rate of 9%, and a recurrent dysphagia rate of 37%, mostly due to stent migration (13% to 29%), tissue overgrowth (10% to 30%), and food impaction (5%).2,16,19 For benign strictures, varying results have been reported. The initial study series in benign esophageal strictures showed promising results, with relief of dysphagia in 80% of patients.8,20,21,22 SEPS seems to result in a meaningful reduction of reactive tissue hyperplasia and safe stent removal owing to the fully covered design and the silicone material. However, results of a later series have shown a high migration rate (up to 62%) and low long-term relief of dysphagia (only 17% to 30% of patients).3,4,5,10 A recent systematic review of 130 patients with a benign esophageal stricture, obtained from 10 studies, showed that after a median follow-up period of 13 months, only 52% of the patients were dysphagia-free, the early migration rate was 24%, the endoscopic reintervention rate was 21%, and major clinical complications occurred in 9% of patients.3 Our systematic review of 172 patients with a benign esophageal stricture, including recent updated reports at the time of writing of this review article, shows the following results: technical success rate of 98%, clinical success rate of 45%, and early stent migration rate of 31% (Table 1).10,12,17,20,23,24,25,26,27,28,29,30

BIODEGRADABLE STENT

Considering that recent studies on SEPS have shown less favorable outcomes, including a disappointing long-term efficacy, high migration rate, and frequent needs for reintervention, the BD stent has been developed as an alternative to SEPS. The currently available BD stent designs are the ELLA-BD stent (ELLA-CS, Hradec Kralove, Czech Republic), which is composed of polydioxanone, a surgical suture material,31 and the poly-L-lactic acid (PLLA)-BD stent (Marui Textile Machinery, Osaka, Japan), which consists of knitted PLLA monofilaments (Table 2).32 These stents can be degraded by hydrolysis, which is accelerated at low ambient pH. Generally, stents begin to degrade after 4 to 5 weeks and dissolve during a period of 2 to 3 months. The major strength of BD stent over SEMS or SEPS is that it does not require removal, even when migrated, and it can be left until it is dissolved by gastric acid, which accelerates hydrolysis, thus avoiding further procedures and potential morbidity.31

Subsequent studies have shown the availability of the PLLA-BD stent, with a low stent-related complication rate, compared with SEMS and SEPS.32,33,34 In these studies, there were no symptoms or need for reintervention within the follow-up period in all cases; however, most of the stents (10 of 13 cases [70%]) had migrated within 10 to 21 days after insertion. Because of this tendency of early stent migration found in those three studies, the natural history of degradation of the PLLA-BD stent within the esophagus and the tolerability of the degradation process over time were not adequately assessed. In contrast to the PLLA-BD stent, the ELLA-BD stent has shown some promising results. An initial case series with the ELLA-BD stent for esophageal strictures, including caustic, peptic, malignant, anastomotic, radiation-induced strictures as well as achalasia, showed a low migration rate (0% to 22%) and an acceptable clinical success rate (33% to 60%).21,31,35,36,37 However, the ELLA-BD stent, not unlike commercially available SEMS and SEPS, can induce significant hyperplastic tissue reactions.31,35,36,37,38 The uncovered design of BD stent allows stent embedding to the esophageal wall and significantly reduces the migration rate; however, it induces considerable reactive tissue hyperplasia. Our systematic review of 111 patients with a benign esophageal stricture obtained from nine studies showed the following results: technical success rate of 96%, clinical success rate of 47%, early stent migration rate of 21%, and tissue hyperplasia rate of 13% (Table 3).12,21,30,32,33,34,35,39,40

Recently modified ELLA-BD stents with a non-BD covering made of polyurethane were used in five patients with esophageal leaks or perforations.41 The initial clinical success rate was 80%; however, the stent migration rate was 60%. Therefore, the effect of the covered design on minimizing the hyperplastic tissue reaction remains an unsolved problem. Recently, drug-eluting BD stents have been introduced as a solution to reactive hyperplasia. Theoretically, localized delivery of drugs such as paclitaxel or rapamycin from drug-eluting stents is a promising treatment method for preventing restenosis or inflammatory cell proliferation. Until now, many experimental studies have been done with animal models.42,43 More studies on the clinical application of drug-eluting BD stents for human patients are needed.

PLASTIC AND BIODEGRADABLE STENTS: BETTER THAN METAL STENT

The main limitations of stent placement in benign strictures are hyperplastic tissue reaction, embedding into the esophageal wall, and stent migration. To avoid these limitations, an optimal stent must have a flexible, nontraumatic design and a diameter large enough for normal food passage. In addition, the procedure for insertion, repositioning, and removal should be simple and minimize stent migration and tissue hyperplasia.2 However, for the treatment of complex and refractory benign esophageal strictures, no ideal stent is yet available. Each type of stent has its own advantages and disadvantages according to the stent characteristics (Table 4). To date, only uncontrolled studies have evaluated the safety and efficacy of various stent designs in patients with benign esophageal strictures. On the basis of the studies published thus far, the long-term outcome according to the stent type is not different and is unsatisfactory (approximately 45%) (Table 5). As previously mentioned, although a partially covered SEMS has a high anchoring capacity owing to the uncovered design at both ends, it shows a high rate of hyperplastic ingrowth or overgrowth through the uncovered mesh, resulting in severe stent embedding and difficulty of safe removal endoscopically. On the other hand, the migration rate is higher when fully covered stents, either SEMS or SEPS, are used. This is because of their reduced anchoring capacity compared with partially covered SEMS. Meanwhile, the BD stent shows reduced migration rate owing to its uncovered design; however, hyperplastic tissue reactions have emerged as a main problem. Up to now, the question of which type of stent should be recommended for the effective treatment of complex and refractory benign strictures has no clear answer. Therefore, the selection of stent type for endoscopic treatment should be individualized, taking into consideration the endoscopist's experience as well as patient and stricture characteristics, especially including the location and cause of the stricture. In the case of sites with an increased risk of migration (i.e., distal esophagus or anastomosis site) or restenting after stent migration, the BD stent may be a reasonable option over SEMS or SEPS. To minimize tissue hyperplasia after BD stent placement, steroid injection or a drug-eluting BD stent may be an effective option. Larger, randomized, prospective, well-designed studies are needed to demonstrate the long-term efficacy and safety of stents at each applicable location within the gastrointestinal tract.

CONCLUSIONS

SEPS and BD stents were developed to decrease the limitations of SEMS for benign complex and refractory esophageal strictures. Early studies on both stents reported excellent results; however, our systematic review does not show a superior clinical outcome of these stents compared with SEMS. Although the ideal stent has not yet been developed, SEPS and BD stents have their own special merits such as decreasing tissue hyperplasia and eliminating the need for stent removal. Therefore, the selection of stent type should be individualized, taking into consideration the endoscopist's experience as well as patient and stricture characteristics. In the future, a new stent that has only the merits of SEMS, SEPS, and BD stents will need to be developed.

Acknowledgments

This work was supported by a 2-year research grant from Pusan National University.

The authors have no financial conflicts of interest.

REFERENCES

1. Siersema PD. Treatment options for esophageal strictures. Nat Clin Pract Gastroenterol Hepatol 2008;5:142–152.Article PubMed
2. Hirdes MM, Vleggaar FP, Siersema PD. Stent placement for esophageal strictures: an update. Expert Rev Med Devices 2011;8:733–755.Article PubMed
3. Repici A, Hassan C, Sharma P, Conio M, Siersema P. Systematic review: the role of self-expanding plastic stents for benign oesophageal strictures. Aliment Pharmacol Ther 2010;31:1268–1275.Article PubMed
4. Kochman ML, McClave SA, Boyce HW. The refractory and the recurrent esophageal stricture: a definition. Gastrointest Endosc 2005;62:474–475.Article
5. Patterson DJ, Graham DY, Smith JL, et al. Natural history of benign esophageal stricture treated by dilatation. Gastroenterology 1983;85:346–350.Article PubMed
6. Spechler SJ. American gastroenterological association medical position statement on treatment of patients with dysphagia caused by benign disorders of the distal esophagus. Gastroenterology 1999;117:229–233.Article PubMed
7. Eloubeidi MA, Talreja JP, Lopes TL, Al-Awabdy BS, Shami VM, Kahaleh M. Success and complications associated with placement of fully covered removable self-expandable metal stents for benign esophageal diseases (with videos). Gastrointest Endosc 2011;73:673–681.Article PubMed
8. Holm AN, de la Mora Levy JG, Gostout CJ, Topazian MD, Baron TH. Self-expanding plastic stents in treatment of benign esophageal conditions. Gastrointest Endosc 2008;67:20–25.Article PubMed
9. Siersema PD, de Wijkerslooth LR. Dilation of refractory benign esophageal strictures. Gastrointest Endosc 2009;70:1000–1012.Article PubMed
10. Dua KS, Vleggaar FP, Santharam R, Siersema PD. Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol 2008;103:2988–2994.Article PubMed
11. Kim JH, Song HY, Choi EK, Kim KR, Shin JH, Lim JO. Temporary metallic stent placement in the treatment of refractory benign esophageal strictures: results and factors associated with outcome in 55 patients. Eur Radiol 2009;19:384–390.Article PubMed
12. van Boeckel PG, Vleggaar FP, Siersema PD. A comparison of temporary self-expanding plastic and biodegradable stents for refractory benign esophageal strictures. Clin Gastroenterol Hepatol 2011;9:653–659.Article PubMed
13. Mercer CD, Hill LD. Surgical management of peptic esophageal stricture. Twenty-year experience. J Thorac Cardiovasc Surg 1986;91:371–378.Article PubMed
14. Little AG, Naunheim KS, Ferguson MK, Skinner DB. Surgical management of esophageal strictures. Ann Thorac Surg 1988;45:144–147.Article PubMed
15. van Boeckel PG, Dua KS, Weusten BL, et al. Fully covered self-expandable metal stents (SEMS), partially covered SEMS and self-expandable plastic stents for the treatment of benign esophageal ruptures and anastomotic leaks. BMC Gastroenterol 2012;12:19.Article PubMed PMC PDF
16. Verschuur EM, Repici A, Kuipers EJ, Steyerberg EW, Siersema PD. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol 2008;103:304–312.Article PubMed
17. Martin RC, Woodall C, Duvall R, Scoggins CR. The use of self-expanding silicone stents in esophagectomy strictures: less cost and more efficiency. Ann Thorac Surg 2008;86:436–440.Article PubMed
18. Pungpapong S, Raimondo M, Wallace MB, Woodward TA. Problematic esophageal stricture: an emerging indication for self-expandable silicone stents. Gastrointest Endosc 2004;60:842–845.Article PubMed
19. Conio M, Repici A, Battaglia G, et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol 2007;102:2667–2677.Article PubMed
20. Repici A, Conio M, De Angelis C, et al. Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc 2004;60:513–519.Article PubMed
21. Repici A, Vleggaar FP, Hassan C, et al. Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc 2010;72:927–934.Article PubMed
22. Thomas T, Abrams KR, Subramanian V, Mannath J, Ragunath K. Esophageal stents for benign refractory strictures: a meta-analysis. Endoscopy 2011;43:386–393.Article PubMed PDF
23. Broto J, Asensio M, Vernet JM. Results of a new technique in the treatment of severe esophageal stenosis in children: poliflex stents. J Pediatr Gastroenterol Nutr 2003;37:203–206.Article PubMed
24. Evrard S, Le Moine O, Lazaraki G, Dormann A, El Nakadi I, Devière J. Self-expanding plastic stents for benign esophageal lesions. Gastrointest Endosc 2004;60:894–900.Article PubMed
25. Triester SL, Fleischer DE, Sharma VK. Failure of self-expanding plastic stents in treatment of refractory benign esophageal strictures. Endoscopy 2006;38:533–537.Article PubMed PDF
26. Barthel JS, Kelley ST, Klapman JB. Management of persistent gastroesophageal anastomotic strictures with removable self-expandable polyester silicon-covered (Polyflex) stents: an alternative to serial dilation. Gastrointest Endosc 2008;67:546–552.Article PubMed
27. García-Cano J. Dilation of benign strictures in the esophagus and colon with the polyflex stent: a case series study. Dig Dis Sci 2008;53:341–346.Article PubMed
28. Karbowski M, Schembre D, Kozarek R, Ayub K, Low D. Polyflex self-expanding, removable plastic stents: assessment of treatment efficacy and safety in a variety of benign and malignant conditions of the esophagus. Surg Endosc 2008;22:1326–1333.Article PubMed
29. Oh YS, Kochman ML, Ahmad NA, Ginsberg GG. Clinical outcomes after self-expanding plastic stent placement for refractory benign esophageal strictures. Dig Dis Sci 2010;55:1344–1348.Article PubMed
30. Canena JM, Liberato MJ, Rio-Tinto RA, et al. A comparison of the temporary placement of 3 different self-expanding stents for the treatment of refractory benign esophageal strictures: a prospective multicentre study. BMC Gastroenterol 2012;12:70.Article PubMed PMC PDF
31. Stivaros SM, Williams LR, Senger C, Wilbraham L, Laasch HU. Woven polydioxanone biodegradable stents: a new treatment option for benign and malignant oesophageal strictures. Eur Radiol 2010;20:1069–1072.Article PubMed
32. Tanaka T, Takahashi M, Nitta N, et al. Newly developed biodegradable stents for benign gastrointestinal tract stenoses: a preliminary clinical trial. Digestion 2006;74:199–205.Article PubMed
33. Saito Y, Tanaka T, Andoh A, et al. Usefulness of biodegradable stents constructed of poly-l-lactic acid monofilaments in patients with benign esophageal stenosis. World J Gastroenterol 2007;13:3977–3980.Article PubMed PMC
34. Saito Y, Tanaka T, Andoh A, et al. Novel biodegradable stents for benign esophageal strictures following endoscopic submucosal dissection. Dig Dis Sci 2008;53:330–333.Article PubMed
35. van Hooft JE, van Berge Henegouwen MI, Rauws EA, Bergman JJ, Busch OR, Fockens P. Endoscopic treatment of benign anastomotic esophagogastric strictures with a biodegradable stent. Gastrointest Endosc 2011;73:1043–1047.Article PubMed
36. Hair CS, Devonshire DA. Severe hyperplastic tissue stenosis of a novel biodegradable esophageal stent and subsequent successful management with high-pressure balloon dilation. Endoscopy 2010;42(Suppl 2):E132–E133.Article PubMed PDF
37. Vandenplas Y, Hauser B, Devreker T, Urbain D, Reynaert H. A biodegradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child. J Pediatr Gastroenterol Nutr 2009;49:254–257.Article PubMed
38. Orive-Calzada A, Alvarez-Rubio M, Romero-Izquierdo S, et al. Severe epithelial hyperplasia as a complication of a novel biodegradable stent. Endoscopy 2009;41(Suppl 2):E137–E138.Article PubMed PDF
39. Hirdes MM, Siersema PD, van Boeckel PG, Vleggaar FP. Single and sequential biodegradable stent placement for refractory benign esophageal strictures: a prospective follow-up study. Endoscopy 2012;44:649–654.Article PubMed PDF
40. Karakan T, Utku OG, Dorukoz O, et al. Biodegradable stents for caustic esophageal strictures: a new therapeutic approach. Dis Esophagus 2013;26:319–322.Article PubMed PDF
41. Černá M, Köcher M, Válek V, et al. Covered biodegradable stent: new therapeutic option for the management of esophageal perforation or anastomotic leak. Cardiovasc Intervent Radiol 2011;34:1267–1271.Article PubMed
42. Zhu YQ, Cui WG, Cheng YS, Chang J, Chen NW, Yan L. Evaluation of biodegradable paclitaxel-eluting nanofibre-covered metal stents for the treatment of benign cardia stricture in an experimental model. Br J Surg 2013;100:784–793.Article PubMed
43. Zhu YQ, Cui WG, Cheng YS, et al. Biodegradable rapamycin-eluting nano-fiber membrane-covered metal stent placement to reduce fibroblast proliferation in experimental stricture in a canine model. Endoscopy 2013;45:458–468.Article PubMed PDF

Fig. 1

Stents currently used for benign esophageal strictures. (A)Niti-S covered stent (Taewoong Medical). (B) Polyflex stent (Boston Scientific). (C) ELLA-BD stent (ELLA-CS).

Table 1

Results of Self-Expanding Plastic Stents in Benign Esophageal Strictures

Values are presented as number (%).

^a)Technical success was defined as the correct positioning of the stent within the stricture; ^b)Early stent migration was defined as the occurrence of stent migration within 4 weeks from stent placement; ^c)Clinical success was defined as clinical remission without the need for further endoscopic dilation or surgery after stent removal or migration.

Table 2

Currently Available Biodegradable Stents for Benign Esophageal Strictures

PLLA, poly-L-lactic acid.

Table 3

Result of Biodegradable Stents in Benign Esophageal Strictures

PLLA, poly-L-lactic acid.

Table 4

Stent Characteristics according to the Stent Type

SEMS, self-expanding metal stent; SEPS, self-expanding plastic stent; BD, biodegradable.

Table 5

Clinical Outcomes according to the Stent Type in Benign Esophageal Strictures

SEMS, self-expanding metal stent; SEPS, self-expanding plastic stent; BD, biodegradable.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Lumen‐apposing metal stents provide early and late clinical benefits for the management of benign gastrointestinal strictures: Is there a role for definitive therapy?
Ethan Pollack, Dalton Norwood, Hector Caceres, Babusai Rapaka, Isaac E. Perry, Usman Barlass, Rachel Mitchell, Jessica McCreight, Shajan Peter, Ramzi Mulki, Ali Ahmed, Kondal Kyanam, Sergio A. Sánchez‐Luna
DEN Open.2025;[Epub] CrossRef
Innovative Design of a 3D Printed Esophageal Stent Inspired by Nature: Mitigating Migration Challenges in Palliative Esophageal Cancer Therapy
Thomas Profitiliotis, Savvas Koltsakidis, Konstantinos Tsongas, Dimitrios Tzetzis
Biomimetics.2024; 9(6): 359. CrossRef
A novel intraoperative Esophagus-Sparing Anastomotic Narrowing Revision (ESANR) technique for patients who underwent esophagojejunostomy: three case reports and a review of the literature
Jian Zhou, Zhenhong Wang, Guobiao Chen, Yi Li, Min Cai, Fathima Shifly Pannikkodan, Xiangzhi Qin, Dan Bai, Zhenbing Lv, Lei Gong, Yunhong Tian
World Journal of Surgical Oncology.2024;[Epub] CrossRef
Experience of Endoscopic Dilatation of Esophageal Strictures in a Tertiary Care Hospital: A Study From Central India
Mohammad Talha Noor, Shreyansh Talera, Rootik Raju Bhai Patel, Nidhesh Khemchandani
Cureus.2024;[Epub] CrossRef
Lumen-apposing metal stents for the treatment of benign gastrointestinal tract strictures: a single-center experience and proposed treatment algorithm
Tala Mahmoud, Azizullah Beran, Fateh Bazerbachi, Reem Matar, Veeravich Jaruvongvanich, Farah Abdul Razzak, Donna Maria Abboud, Eric J. Vargas, John A. Martin, Todd A. Kellogg, Omar M. Ghanem, Bret T. Petersen, Michael J. Levy, Ryan J. Law, Vinay Chandrase
Surgical Endoscopy.2023; 37(3): 2133. CrossRef
Caustic esophageal stenosis: A case report of endoscopic dilatation with nasogastric tubes
Esau Ogei, Jackson Kakooza, Catherine R. Lewis
Clinical Case Reports.2023;[Epub] CrossRef
Comprehensive review of materials, applications, and future innovations in biodegradable esophageal stents
Yaochen Yang, Yuanyuan Yang, Zhipeng Hou, Tingting Wang, Peng Wu, Lufan Shen, Peng Li, Kai Zhang, Liqun Yang, Siyu Sun
Frontiers in Bioengineering and Biotechnology.2023;[Epub] CrossRef
Palliative Endoskopie
Benno Arnstadt, Hans-Dieter Allescher
Der Chirurg.2022; 93(3): 310. CrossRef
Safety and efficacy of esophageal stents for esophageal anastomotic strictures: A 10-year single-center experience
Sundus Bilal, Saad Muhammad Saeed, Zeeshan Siddique, Muhammad Saqib, Shahana Shahid, Muhammed Aasim Yusuf
International Journal of Gastrointestinal Intervention.2022; 11(2): 72. CrossRef
Benign Esophageal Stricture
Hyun Lim
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2022; 22(3): 197. CrossRef
Mechanical properties and degradation process of biliary self‐expandable biodegradable stents
Chang‐Il Kwon, Jun Sik Son, Kyu Seok Kim, Jong Pil Moon, Sehwan Park, Jinkyung Jeon, Gwangil Kim, Sung Hoon Choi, Kwang Hyun Ko, Seok Jeong, Don Haeng Lee
Digestive Endoscopy.2021; 33(7): 1158. CrossRef
Managing esophageal strictures following endoscopic resection of superficial neoplastic lesions
Alberto Álvarez Delgado, Maria Luis Pérez García
Revista Española de Enfermedades Digestivas.2021;[Epub] CrossRef
Biodegradable Stent/Tube for Pancreatic and Biliary Disease
Chang-Il Kwon
The Korean Journal of Pancreas and Biliary Tract.2020; 25(1): 18. CrossRef
An Overview of the Design, Development and Applications of Biodegradable Stents
Keerthana Nakka, Sri D. Nagarajan, Balamayilsamy Sundaravadivel, Subramanian Shankaravel, Christopher Vimalson
Drug Delivery Letters.2020; 10(1): 2. CrossRef
Alternative uses of lumen apposing metal stents
Prabin Sharma, Thomas R McCarty, Ankit Chhoda, Antonio Costantino, Caroline Loeser, Thiruvengadam Muniraj, Marvin Ryou, Christopher C Thompson
World Journal of Gastroenterology.2020; 26(21): 2715. CrossRef
Corrosive injury of the upper gastrointestinal tract: the evolving role of a radiologist
Ayushi Agarwal, Deep Narayan Srivastava, Kumble Seetharama Madhusudhan
The British Journal of Radiology.2020;[Epub] CrossRef
Improving stent efficiency by understanding stent-related adverse events
Daniel B. Maselli, Andrew C. Storm, Reem Matar, Barham K. Abu Dayyeh
Techniques and Innovations in Gastrointestinal Endoscopy.2020; 22(4): 232. CrossRef
Management of tracheo-oesophageal fistula in adults
Hyun S. Kim, Danai Khemasuwan, Javier Diaz-Mendoza, Atul C. Mehta
European Respiratory Review.2020; 29(158): 200094. CrossRef
3D-printed flexible polymer stents for potential applications in inoperable esophageal malignancies
Maohua Lin, Negar Firoozi, Chi-Tay Tsai, Michael B. Wallace, Yunqing Kang
Acta Biomaterialia.2019; 83: 119. CrossRef
A Review of Self-Expanding Esophageal Stents for the Palliation Therapy of Inoperable Esophageal Malignancies
Yunqing Kang
BioMed Research International.2019; 2019: 1. CrossRef
Clinical outcomes of lumen-apposing metal stent in the management of benign gastrointestinal strictures: a systematic review and meta-analysis
Shali Tan, Chunyu Zhong, Shu Huang, Xujuan Luo, Jin Xu, Xiangsheng Fu, Yan Peng, Xiaowei Tang
Scandinavian Journal of Gastroenterology.2019; 54(7): 811. CrossRef
Novel Uses of Lumen-Apposing Metal Stents
Monica Saumoy, Clark Yarber, Michel Kahaleh
Gastrointestinal Endoscopy Clinics of North America.2018; 28(2): 197. CrossRef
Biodegradable Stents in Resistant Peptic Oesophageal Stricture: Is It the Right Way to Go?
Tom Richardson, Gerlin Naidoo, Namal Rupasinghe, Howard Smart, Sayantan Bhattacharya
Clinical Medicine Insights: Gastroenterology.2018;[Epub] CrossRef
Current trends in the diagnosis and treatment of gastroesophageal reflux disease
Radek Kroupa, Štefan Konečný, Jiří Dolina
Vnitřní lékařství.2018; 64(6): 588. CrossRef
Technical feasibility and tissue reaction after silicone-covered biodegradable magnesium stent insertion in the oesophagus: a primary study in vitro and in vivo
Yue-Qi Zhu, Laura Edmonds, Li-Ming Wei, Rei-La Zheng, Ruo-Yu Cheng, Wen-Guo Cui, Ying-Sheng Cheng
European Radiology.2017; 27(6): 2546. CrossRef
Use of a lumen-apposing metal stent to treat GI strictures (with videos)
Shayan Irani, Sujai Jalaj, Andrew Ross, Michael Larsen, Ian S. Grimm, Todd H. Baron
Gastrointestinal Endoscopy.2017; 85(6): 1285. CrossRef
Use of self-expandable plastic stents (SEPS) in management of refractory benign esophageal strictures: a single center experience
Mohamed Abdel Fattah Selimah, Moustafa Ramadan Abo Elsoud
Esophagus.2017; 14(2): 159. CrossRef
Endoscopic treatment of benign esophageal strictures: a literature review
Laurent Poincloux, Olivier Rouquette, Armand Abergel
Expert Review of Gastroenterology & Hepatology.2017; 11(1): 53. CrossRef
Silicone-covered biodegradable magnesium-stent insertion in the esophagus: a comparison with plastic stents
Yue-Qi Zhu, Kai Yang, Laura Edmonds, Li-Ming Wei, Reila Zheng, Ruo-Yu Cheng, Wen-Guo Cui, Ying-Sheng Cheng
Therapeutic Advances in Gastroenterology.2017; 10(1): 11. CrossRef
Management of esophageal caustic injury
Mark Anthony A De Lusong, Aeden Bernice G Timbol, Danny Joseph S Tuazon
World Journal of Gastrointestinal Pharmacology and Therapeutics.2017; 8(2): 90. CrossRef
Stent-in-stent technique for removal of embedded partially covered self-expanding metal stents
Tomas DaVee, Shayan Irani, Cadman L. Leggett, Manuel Berzosa Corella, Karina V. Grooteman, Louis-Michel Wong Kee Song, Michael B. Wallace, Richard A. Kozarek, Todd H. Baron
Surgical Endoscopy.2016; 30(6): 2332. CrossRef
Caustic Esophageal Stenosis: A Case Report of Endoscopic Dilation With a Dynamic Stent
Marlene Abreu, Isabel Nunes, Susana Corujeira, Marta Tavares, Eunice Trindade, Jorge Amil Dias
GE Portuguese Journal of Gastroenterology.2016; 23(4): 218. CrossRef
A Comparison of a Fully Covered and an Uncovered Segmented Biodegradable Esophageal Stent in a Porcine Model: Preclinical Evaluation of Degradation, Complications, and Tissue Reactions
Yadong Feng, Chunhua Jiao, Yang Cao, Ye Zhao, Yanfang Chen, Lin Fang, Ruihua Shi
Gastroenterology Research and Practice.2016; 2016: 1. CrossRef
Therapy of caustic ingestion
Mitchell D. Shub
Current Opinion in Pediatrics.2015; 27(5): 609. CrossRef
Refractory Esophageal Strictures: What To Do When Dilation Fails
Petra G. A. van Boeckel, Peter D. Siersema
Current Treatment Options in Gastroenterology.2015; 13(1): 47. CrossRef
Foregut caustic injuries: results of the world society of emergency surgery consensus conference
Luigi Bonavina, Mircea Chirica, Ognjan Skrobic, Yoram Kluger, Nelson A. Andreollo, Sandro Contini, Aleksander Simic, Luca Ansaloni, Fausto Catena, Gustavo P. Fraga, Carlo Locatelli, Osvaldo Chiara, Jeffry Kashuk, Federico Coccolini, Yuri Macchitella, Mass
World Journal of Emergency Surgery.2015;[Epub] CrossRef
Caustic injury of the oesophagus
Alastair J. W. Millar, Sharon G. Cox
Pediatric Surgery International.2015; 31(2): 111. CrossRef
Efficacy and histopathological esophageal wall damage of biodegradable esophageal stents for treatment of severe refractory esophageal anastomotic stricture in a child with long gap esophageal atresia
Yuichi Okata, Chieko Hisamatsu, Yuko Bitoh, Akiko Yokoi, Eiji Nishijima, Kosaku Maeda, Makiko Yoshida, Tsukasa Ishida, Takeshi Azuma, Hiromu Kutsumi
Clinical Journal of Gastroenterology.2014; 7(6): 496. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Plastic and Biodegradable Stents for Complex and Refractory Benign Esophageal Strictures

Clin Endosc. 2014;47(4):295-300. Published online July 28, 2014

DOI: https://doi.org/10.5946/ce.2014.47.4.295

XML Download

Figure

Plastic and Biodegradable Stents for Complex and Refractory Benign Esophageal Strictures

Fig. 1 Stents currently used for benign esophageal strictures. (A)Niti-S covered stent (Taewoong Medical). (B) Polyflex stent (Boston Scientific). (C) ELLA-BD stent (ELLA-CS).

Fig. 1

Plastic and Biodegradable Stents for Complex and Refractory Benign Esophageal Strictures

Table 1

Results of Self-Expanding Plastic Stents in Benign Esophageal Strictures

Values are presented as number (%).

Table 2

Currently Available Biodegradable Stents for Benign Esophageal Strictures

PLLA, poly-L-lactic acid.

Table 3

Result of Biodegradable Stents in Benign Esophageal Strictures

PLLA, poly-L-lactic acid.

Table 4

Stent Characteristics according to the Stent Type

SEMS, self-expanding metal stent; SEPS, self-expanding plastic stent; BD, biodegradable.

Table 5

Clinical Outcomes according to the Stent Type in Benign Esophageal Strictures

SEMS, self-expanding metal stent; SEPS, self-expanding plastic stent; BD, biodegradable.

Table 1 Results of Self-Expanding Plastic Stents in Benign Esophageal Strictures

Values are presented as number (%).

Table 2 Currently Available Biodegradable Stents for Benign Esophageal Strictures

PLLA, poly-L-lactic acid.

Table 3 Result of Biodegradable Stents in Benign Esophageal Strictures

PLLA, poly-L-lactic acid.

Table 4 Stent Characteristics according to the Stent Type

SEMS, self-expanding metal stent; SEPS, self-expanding plastic stent; BD, biodegradable.

Table 5 Clinical Outcomes according to the Stent Type in Benign Esophageal Strictures

SEMS, self-expanding metal stent; SEPS, self-expanding plastic stent; BD, biodegradable.